BACKGROUND: Diagnosing giant cell-rich bone tumors can be challenging on limited biopsies. H3 histone family member 3A (H3F3A) (G34W/V/R/L) mutations are present in the majority of giant cell tumors (GCTs) of bone and H3 histone family member 3B (H3F3B) (K36M) mutations are present in nearly all chondroblastomas, but are absent in histologic mimics.
INTRODUCTION
Giant cell-rich primary bone tumors are defined by the presence of prominent osteoclasts or osteoclast-like giant cells and include giant cell tumor (GCT) of bone, GCT of Paget disease, chondroblastoma, aneurysmal bone cyst, and a subset of osteosarcomas. 1 Correlation with clinical and radiologic characteristics, such as tumor site and patient age (indicative of an immature vs mature skeleton), is critical to establish a correct diagnosis. A clear distinction of benign or locally aggressive tumors (ie, conventional GCT, chondroblastoma, or aneurysmal bone cyst) from malignant GCT or osteosarcoma is of paramount importance, with a substantial impact on prognosis and clinical management. 2, 3 GCT of bone has a predilection for young adults with a mature skeleton and usually arises in the epiphysis of long bones. 4 Fewer than 10% of GCTs of bone demonstrate malignant transformation and/or distant metastatic spread. In contrast, chondroblastoma occurs in children and adolescents with an immature skeleton and involves the epiphysis of long bones, with or without extension into the articular cartilage. 4 Aneurysmal bone cysts usually affect patients in their first 2 decades of life with a slight female predominance, and is most common in the metaphysis of long bones. 4 Osteosarcoma usually occurs in the metadiaphysis of the long bones of adolescents and young adults, with a male predominance. 4 Although the diagnosis of giant cell-rich bone tumors on surgical curetting or excision specimens usually is straightforward, the evaluation of these tumors on small biopsies, such as fine-needle aspiration (FNA) or core needle biopsy (CNB), can be challenging, [5] [6] [7] [8] [9] [10] especially in tumors that arise in unusual anatomic sites and/or show atypical morphologic features. With the increasing use of minimally invasive procedures to obtain samples for the initial diagnosis of bone tumors in recent years, recognition of a spectrum of clinical, radiologic, and morphologic features, with the judicious application of immunohistochemical and/or genetic studies, becomes essential in the evaluation of many primary bone tumors. Recently, highly recurrent somatic driver mutations in H3 histone family member 3A (H3F3A) (located at 1q42.12) and H3 histone family member 3B (H3F3B) (located at 17q25.1) encoding replication-independent histone proteins (H3.3) of identical amino acid sequence have been identified in 92% of GCTs of bone and 95% of chondroblastomas, respectively. 11 In GCT of bone, H3F3A G34W mutations are most common (85%-95%), but alternate G34V, G34R, and G34L mutations have been reported in a subset of cases. [11] [12] [13] [14] [15] Chondroblastomas harbor K36M mutations in >90% of cases, resulting from H3F3B mutations and rarely from H3F3A mutations. 11, 15 Other giant cell-rich bone tumors, such as aneurysmal bone cyst and giant cell-rich osteosarcoma, lack these mutations with very rare exceptions. 11, 13, 14, 16 Immunohistochemistry (IHC) using monoclonal antibodies directed against the mutant H3.3G34W and H3.3K36M proteins has been shown to be highly specific for the diagnosis of GCT of bone 17 and chondroblastoma, 18 respectively, on surgical excision specimens. In GCT of bone and chondroblastoma, H3F3A and H3F3B mutations as well as resulting mutant H3.3G34W and H3.3K36M proteins are restricted to the mononuclear stromal cell population and are absent in nonneoplastic multinucleated giant cells and their precursors.
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Although H3F3A sequencing previously has been shown to detect mutations in approximately 90% of GCTs of bone in CNB samples, 14 to the best of our knowledge, IHC for H3G34W and H3K36M has not been systematically studied in FNA and/or CNB specimens. The objective of the current study was to validate the H3G34W and H3K36M mutation-specific antibodies in the diagnosis of giant cell-rich bone tumors on FNA and CNB specimens, with correlation of H3F3A and H3F3B Sanger sequencing in a subset of cases.
MATERIALS AND METHODS

Tumor Samples
Cases 
RESULTS
Clinicopathologic, IHC, and genomic data for all 55 patients with giant cell-rich bone tumors are summarized in Table 1 .
Clinicopathologic Findings
Among the 26 patients with GCTs of bone, 14 were male and 12 female with a median age of 32.5 years (range, 17-84 years). Conventional GCT of bone was found for the most part in the lower extremity (13 cases), followed by the limb girdle (5 cases), upper extremity (5 cases), and trunk (1 case). The 2 malignant GCTs of bone arose in the lower extremity and trunk, respectively. The single case of GCT of Paget disease arose in the humerus of an 88-year-old man with Paget disease who presented clinically with pathologic fracture. Of the 8 patients with chondroblastoma, 4 were male and 4 were female with a median age of 23.5 years (range, 13-28 years). Chondroblastomas were located in the lower extremity (5 cases), upper extremity (2 cases), and limb girdle (1 case). All 7 patients with aneurysmal bone cyst were female with a median age of 21 years (range, 10-33 years). Aneurysmal bone cysts were located in the lower extremity (3 cases), upper extremity (2 cases), limb girdle (1 case), and trunk (1 case). Thirteen patients with osteosarcoma comprised 5 males and 8 females with a median age of 40 years (range, 18-72 years); the tumors for the most part were located in the lower extremity (10 cases) or limb girdle (3 cases).
The original diagnoses of patients with GCT of bone or chondroblastoma on FNA, CNB, and curettage/excision specimens are summarized in Table 2 .
In 26 patients, the diagnosis of GCT of bone was established on FNA alone (3 cases, including 2 cases with nondiagnostic concurrent CNB specimens), CNB alone (10 cases, including 2 cases with inconclusive concurrent FNA specimens), FNA with concurrent CNB specimens (11 cases), and on curetting/excision (2 cases). In the last 2 cases, indefinite diagnoses such as "giant cell-rich (Figs. 1A and 1B) . The GCT of Paget disease was cytomorphologically indistinguishable from GCT of bone (data not shown).
Of the 8 cases of chondroblastoma, 2 were diagnosed on FNA with concurrent CNB specimens, 5 cases were diagnosed on CNB alone, and 1 case was diagnosed on surgical curetting (Table 2) . Two FNA cases of chondroblastoma demonstrated characteristic cellular smears with clusters of uniformly round to oval cells with loose matrix 
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Original Article material and scattered multinucleated giant cells. The tumor cells showed well-delineated cell borders, clear to vacuolated cytoplasm, and oval nuclei with longitudinal grooves (Figs. 1C and 1D) . Case 3 was a chondroblastoma arising in the calcaneus of a 28-year-old man. The initial FNA was diagnosed as aneurysmal bone cyst and the concurrent CNB specimen was nondiagnostic. This tumor was reclassified as chondroblastoma after re-review of the curetting. The FNA specimens of this case were very sparsely cellular with occasional oval epithelioid cells and osteoclast-like giant cells in a bloody background, and the cell block sections demonstrated scant mononuclear cells with admixed multinucleated giant cells and dense eosinophilic matrix. In 7 patients, aneurysmal bone cyst was diagnosed on FNA with a concurrent CNB specimen in 4 cases, on CNB alone in 2 cases, and on FNA alone in 1 case. FNA specimens demonstrated small fragments of spindle cells with admixed multinucleated giant cells in a prominent hemorrhagic background ( Figs. 2A and 2B ). Eleven cases of osteosarcoma were diagnosed on FNA with concurrent CNB specimens whereas 2 cases were diagnosed on FNA alone. The FNA specimens exhibited loosely cohesive pleomorphic tumor cells with admixed multinucleated giant cells (Figs. 2C and 2D ).
Immunohistochemistry
For GCTs of bone, IHC for H3G34W was positive in 22 of 26 cases (85%) with at least 2 positive specimens. Of a total of 78 specimens ( 
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H3G34W/H3K36M in Giant Cell-Rich Tumors/Schaefer et al and G34L mutations (see Sanger sequencing below), which are not detected by the H3G34W antibody. In 2 CNB cases ( Table 2 , case 16 and case 20), "benign histiocytic proliferation" and "nondiagnostic" were reported, but IHC for H3G34W highlighted the few neoplastic cells in these CNB samples. IHC for H3G34W demonstrated positive staining in all 3 samples (FNA, CNB, and excision) of a "giant cell-rich tumor" in the distal femur of an 83-year-old woman with unusual histology showing extensive hyalinization (case 24), and therefore the diagnosis of GCT of bone finally was confirmed. In all positive cases, only the mononuclear stromal cells were positive for H3G34W and the nonneoplastic multinucleated giant cells and histiocytes were negative (Fig. 3A) .
In 1 malignant GCT of bone (case 33) that originally was classified as GCT of bone on FNA and CNB, a diagnosis of osteosarcoma (variably chondroblastoma-like or giant cell-rich) was made on the surgical resection specimen based on the presence of areas with significant cytologic atypia and the consultation opinions from multiple bone pathology experts worldwide. The tumor cells expressed H3G34W on all the biopsy and resection specimens (Fig. 4A-D) , thereby supporting the diagnosis of malignant GCT of bone. The second malignant GCT of bone (case 34) initially was diagnosed as GCT of bone on both FNA and CNB specimens, but recurred 32 months later as "high-grade spindle cell sarcoma, suggestive of osteosarcoma" on the repeat CNB and subsequent surgical resection specimen (Fig. 5A and 5C ). This case was negative for H3G34W in both biopsy and resection specimens but was shown to harbor an alternate H3F3A mutation (see below and Fig. 5B and 5D ). Neoadjuvant and/or denosumab therapy appeared to have no effect on H3G34W expression in any of these cases.
The 3 conventional H3G34W-negative GCTs of bone demonstrated classic clinical presentations and arose in the distal femur of a 22-year-old woman (case 9), in the sacrum of a 20-year-old woman (case 13), and in the proximal femur of a 25-year-old man (case 23) (Fig. 6) .
In cases of chondroblastoma, IHC for H3K36M was found to be positive in all 8 cases (100%). The positive staining was detected in a total of 13 of 18 biopsy and excision specimens (72%), including 3 of 3 FNA specimens (100%), 6 of 7 CNB specimens (86%), and 4 of 8 curettings (50%). Positive H3K36W IHC nuclear staining highlighted mononuclear tumor cells only (Fig. 7B) .
All GCTs of bone were negative for H3K36M (Table 1) (Fig. 7A) , and all chondroblastoma cases were negative for H3G34W (Fig. 3B) .
All biopsy and excision specimens for the cases of GCT of Paget disease (1 case), aneurysmal bone cysts (7 cases), and osteosarcoma (13 cases) were negative for both H3G34W and H3K36M (Table 1) (Figs. 3C to 3D and Figs. 7C to 7D, respectively) .
Taken together, the specificity and sensitivity of H3G34W IHC for the diagnosis of GCTs of bone among giant cell-rich bone tumors were 100% and 85%, respectively. Both the specificity and sensitivity of H3K36M IHC for the diagnosis of chondroblastoma were 100%. IHC was concordant between the biopsy and surgical specimens in 152 of 158 samples (96%). All 42 FNA specimens demonstrated concordant IHC results with concurrent CNB and/or subsequent excision specimens. Six of 158 specimens for which previous or subsequent samples demonstrated positive staining for H3G34W or H3K36M were negative, including 2 CNB samples and 4 curetting/excision specimens.
Sanger Sequencing
Two GCTs of bone that were negative for H3G34W on IHC were found to have alternate H3F3A codon 34 mutations: case 23 harbored an alternate H3F3A G34V mutation (c.104G>T) (mutant allele fraction of approximately 15%) (Fig. 6) and case 34 harbored an alternate H3F3A G34L mutation (c.103_104GG>TT) (mutant allele fraction of approximately 40%) (Fig. 5) . As expected, one H3G34W-positive malignant GCT of bone (case 33) harbored an H3F3A G34W mutation (c.103G>T;p.G34W) (mutant allele fraction of approximately 30%) (Fig. 4) . All 3 cases were H3F3B wild-type (data not shown). No H3F3A or H3F3B mutations could be detected in the remaining 2 H3G34W IHC-negative GCTs of bone and the GCT of Paget disease (data not shown). As expected, sequence analyses in an H3K36M-positive chondroblastoma (case 3) demonstrated an H3F3B K36M (c.110A>T) mutation (Fig. 8 ) and did not demonstrate an H3F3A mutation. 
DISCUSSION
The utility of FNA and/or CNB in the evaluation of primary bone tumors currently is limited to a few large tertiary centers 10, 21 due to a combination of the uneasiness of general cytopathologists with regard to primary bone tumors, a high insufficient rate in certain tumors, 6 mounting challenges in distinguishing highly malignant giant cell-rich osteosarcoma from locally aggressive giant cellrich neoplasms such as GCT of bone and chondroblastoma, [7] [8] [9] [10] and the lack of helpful diagnostic markers for these difficult differential diagnoses. Recent advances in understanding the underlying genetics in bone tumors, notably H3.3 mutations in GCT of bone and chondroblastoma, 11 have not only broadened our understanding of the pathogenesis of these bone tumors but also have provided us with novel diagnostic tools, thereby opening a new era of using FNA and/or CNB in the evaluation of primary bone tumors. G34L mutations were excluded. In the current study, using the same rabbit monoclonal antibody, IHC for H3G34W demonstrated a slightly lower but similar sensitivity of 85% of all cases including 2 cases with alternate mutations. Therefore, in tumors with an otherwise classic morphology and clinical presentation, negative H3G34W staining should not exclude a diagnosis of GCT of bone. Sequencing analysis and/or additional IHC with variant mutant-specific antibodies may aid in confirming the diagnosis, if necessary. 22 The reported frequency of H3F3A mutations in GCT of bone appears to depend on the sequencing approaches, and ranges from 69% for Sanger sequencing 13 to 96% for targeted massively parallel sequencing. 16 With a detection rate of approximately 15% to 20% mutant alleles, 23 Sanger sequencing may not always be sensitive enough and previously was shown to miss an H3F3A mutation at a mutant allele fraction of 12%, which was detected by pyrosequencing. 14 Because nonneoplastic cells constitute up to 50% of cells in GCT of bone and chondroblastoma, Sanger sequencing may lead to falsenegative results. Case 23 in the current study demonstrated low mutant allele fractions of only approximately 15% (Fig. 6E ), reaching just above the threshold of detection for Sanger sequencing. Therefore, it is possible that the 2 remaining cases of H3G34W-negative GCT of bone in the current study, which appeared to be wild-type, harbored H3.3 G34 mutations at allele fractions that were beyond the sensitivity of detection. Cases 33 and 34 illustrate the challenges of distinguishing malignant GCT of bone from osteosarcoma (even in excision specimens) based on morphology alone. In case 33 with a confirmed H3F3A G34W mutation, IHC for H3G34W was positive in biopsy samples demonstrating conventional GCT of bone as well as on the final surgical resection specimen showing morphologic features of chondroblastoma-like osteosarcoma, thus confirming the diagnosis of GCT of bone with malignant transformation (Fig. 4) . In case 34, IHC for H3G34W was negative in the initial FNA/CNB, which demonstrated morphology of classic GCT of bone, in the FNA/CNB obtained at the time of disease recurrence, as well as in the surgical resection specimen showing a malignant spindle cell neoplasm. In conjunction with aggressive imaging features, the morphologic findings of a malignant spindle cell neoplasm were interpreted as osteosarcoma. Sanger sequencing revealed an alternate H3F3A G34L mutation, which is not detected by the mutation-specific H3G34W antibody, thereby supporting the belief that this "osteosarcoma" in fact represents malignant transformation of GCT of bone (Fig. 5) .
H3.3 G34W/G34R mutations have been reported in rare cases of osteosarcoma and chondrosarcoma. 11, 14, 17 In agreement with Amary et al, 17 we believe that such cases represent malignancy in GCT of bone rather than true osteosarcoma. In a recent study, 6 of 106 osteosarcomas were found to harbor H3F3A hotspot mutations, including H3.3 G34W, G34R, and K27M. 24 However, the authors demonstrated that the DNA methylation profiles of these H3.3 G34-mutant osteosarcomas differed from H3F3 wild-type osteosarcomas and were more closely related to GCT of bone, 24 further supporting the view that these tumors could represent malignant GCT of bone rather than osteosarcoma.
In the current study, the treatment of patients with GCT of bone with denosumab, chemotherapy, or radiotherapy did not appear to alter the intensity or extent of H3G34W staining, in keeping with the findings reported in a very recent study by Yamamoto et al. 22 In contrast,
Luke et al reported a reduction in the H3G34W-positive cells in GCT of bone after treatment with denosumab. 25 At the molecular level, conflicting results also have been reported. Although some groups demonstrated preservation of the H3F3A mutation in 2 cases of GCT of bone after denosumab therapy, 20 others found an apparent loss of mutant alleles after treatment in 2 of 3 cases. 14 In the current study, the H3F3A G34L mutation was detected in surgical resection specimens after treatment with denosumab (case 34). Additional study is needed to clarify these conflicting results. Similar to the results reported by Amary et al, 18 the results of the current study indicate that H3K36M IHC was highly sensitive and specific for the diagnosis of chondroblastoma, and was found to be positive in all 8 cases (100%) and negative in all histologic mimics. The ability of H3K36M IHC to detect a few clusters of chondroblastoma cells on FNA cell block sections highlights the diagnostic value of the mutation-specific IHC in very scant FNA specimens. The calcaneus tumor from a 28-year-old man (case 3) initially was misdiagnosed as an aneurysmal bone cyst on FNA. The histology on surgical curetting demonstrated features typical of chondroblastoma and the diagnosis was confirmed further by H3K36M positivity and by the presence of an H3F3B mutation by Sanger sequencing (Fig. 8 ).
In the current series, the original diagnosis was changed in 3 of 34 tumors (8.8%) ( Table 2 ) based on the results of IHC (2 cases; cases 3 and 33) and Sanger sequencing (1 case; case 34). IHC for H3G34W would have helped to establish the definitive diagnosis of GCT of bone in an additional 4 FNA cases and 4 CNB cases, in which only nondiagnostic, benign histiocytic proliferation, or equivocal "giant cell-rich neoplasm" diagnoses were rendered. These results highlight the diagnostic value of mutation-specific antibodies in difficult cases, especially in FNA/CNB specimens.
Although giant cell reparative granuloma (mostly located in the jaw) and brown tumor of hyperparathyroidism enter the differential diagnosis of giant cell-rich bone tumors on small biopsies, these lesions are rare and infrequently sampled by FNA. Therefore, we were not able to include these entities in the current study. However, previous studies performed on surgical resections by Amary et al 18 and Yamamoto et al 22 included large numbers of cases of giant cell granuloma of the jaw, fibrous dysplasia, tenosynovial GCT, and brown tumors, none of which were found to express H3G34W or H3K36M by IHC.
The findings of the current study confirm the high specificity of mutation-specific H3G34W and H3K36M antibodies for the diagnosis of GCT of bone and chondroblastoma respectively, in FNA and CNB specimens, which often are the first samples to be evaluated in the diagnostic workup of giant cell-rich bone tumors. These markers are of high diagnostic usefulness, especially in certain challenging settings when clinicoradiologic presentations and/or cytomorphologic features are not definitive. The presence of alternate H3F3A mutations accounts for H3G34W IHC negativity in a subset of GCT of bone cases. The detection of H3F3A mutations by H3G34W IHC and/or by sequencing in malignant tumors arising from GCT of bone aids in the distinction between malignant GCT of bone and osteosarcoma.
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